Integral Health Asset Management LLC Purchases Shares of 100,000 SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

Integral Health Asset Management LLC purchased a new stake in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 100,000 shares of the company’s stock, valued at approximately $3,613,000.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Huntington National Bank lifted its stake in shares of SpringWorks Therapeutics by 38.2% during the fourth quarter. Huntington National Bank now owns 694 shares of the company’s stock worth $25,000 after purchasing an additional 192 shares in the last quarter. AlphaQuest LLC lifted its stake in shares of SpringWorks Therapeutics by 70.2% during the fourth quarter. AlphaQuest LLC now owns 1,004 shares of the company’s stock worth $36,000 after purchasing an additional 414 shares in the last quarter. Barclays PLC lifted its stake in shares of SpringWorks Therapeutics by 0.3% during the fourth quarter. Barclays PLC now owns 156,123 shares of the company’s stock worth $5,641,000 after purchasing an additional 447 shares in the last quarter. Virtus ETF Advisers LLC lifted its stake in shares of SpringWorks Therapeutics by 7.4% during the fourth quarter. Virtus ETF Advisers LLC now owns 9,037 shares of the company’s stock worth $327,000 after purchasing an additional 622 shares in the last quarter. Finally, KBC Group NV lifted its stake in shares of SpringWorks Therapeutics by 59.1% during the fourth quarter. KBC Group NV now owns 2,634 shares of the company’s stock worth $95,000 after purchasing an additional 978 shares in the last quarter.

Insider Transactions at SpringWorks Therapeutics

In other SpringWorks Therapeutics news, CEO Saqib Islam sold 49,000 shares of the firm’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $54.24, for a total transaction of $2,657,760.00. Following the transaction, the chief executive officer now directly owns 954,869 shares in the company, valued at $51,792,094.56. This trade represents a 4.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Badreddin Edris sold 20,000 shares of SpringWorks Therapeutics stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $54.23, for a total value of $1,084,600.00. Following the completion of the transaction, the chief operating officer now owns 169,712 shares in the company, valued at $9,203,481.76. The trade was a 10.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 158,016 shares of company stock valued at $9,102,946. 7.83% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of research analysts have commented on SWTX shares. Evercore ISI cut SpringWorks Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, April 28th. Cowen cut SpringWorks Therapeutics to a “hold” rating in a research note on Tuesday, April 29th. Guggenheim cut SpringWorks Therapeutics from a “buy” rating to a “neutral” rating and cut their price target for the stock from $77.00 to $47.00 in a research note on Monday, April 28th. Wedbush reiterated a “neutral” rating and issued a $47.00 price target (down previously from $81.00) on shares of SpringWorks Therapeutics in a research note on Monday, April 28th. Finally, Barclays reiterated an “equal weight” rating and issued a $47.00 price target (down previously from $63.00) on shares of SpringWorks Therapeutics in a research note on Monday, April 28th. Seven analysts have rated the stock with a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat, SpringWorks Therapeutics presently has an average rating of “Hold” and a consensus price target of $52.57.

SpringWorks Therapeutics Stock Performance

Shares of NASDAQ:SWTX opened at $46.26 on Monday. SpringWorks Therapeutics, Inc. has a one year low of $28.21 and a one year high of $62.00. The stock has a fifty day moving average of $44.35 and a 200-day moving average of $41.76. The company has a market capitalization of $3.47 billion, a PE ratio of -13.29 and a beta of 0.77.

SpringWorks Therapeutics (NASDAQ:SWTX) last released its earnings results on Friday, May 9th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.81) by ($0.30). The business had revenue of $49.09 million during the quarter, compared to analysts’ expectations of $64.19 million. SpringWorks Therapeutics had a negative net margin of 134.73% and a negative return on equity of 46.74%. As a group, research analysts forecast that SpringWorks Therapeutics, Inc. will post -2.05 EPS for the current fiscal year.

SpringWorks Therapeutics Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.